Mainstream

Insmed Targets $405m $425m Arikayce Revenue For 2025 While Advancing Brensocatib And Tpip Programs

Insmed targets $405M-$425M ARIKAYCE revenue for 2025 while advancing brensocatib and TPIP programs

Insmed targets $405M-$425M ARIKAYCE revenue for 2025 while advancing brensocatib and TPIP programs

Post ContentinsmRead More

You might also be interested in reading Five Years After GameStop Chaos, Robinhood Again Sanctioned by FINRA for $29.75 Million.

February 20, 2025
In Mainstream